Extended surgical resection in stage III non-small cell lung cancer.

Frontiers of Radiation Therapy and Oncology Pub Date : 2010-01-01 Epub Date: 2009-11-24 DOI:10.1159/000262466
Sven Hillinger, Walter Weder
{"title":"Extended surgical resection in stage III non-small cell lung cancer.","authors":"Sven Hillinger,&nbsp;Walter Weder","doi":"10.1159/000262466","DOIUrl":null,"url":null,"abstract":"<p><p>Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low.</p>","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"42 ","pages":"115-121"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000262466","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Radiation Therapy and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000262466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/11/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
扩大手术切除III期非小细胞肺癌。
III期包括各种各样的临床情况,从胸壁侵犯并肺叶内淋巴结转移到任何大小的肺癌并纵隔淋巴结受累(N2/N3)。此外,淋巴结转移患者的预后在很大程度上取决于疾病的程度,其范围可能从手术中偶尔发现的微转移到纵隔或囊外浸润的大块和/或多层转移。对于IIIA期(N2)和IIIB期(T4/N3)非小细胞肺癌的最佳治疗方法,包括手术的作用存在争议,这并不奇怪。充分分析临床分期是选择最佳治疗方案的关键。一般来说,患者受益于手术,因为根治性切除可以实现低发病率和死亡率。在大多数诊断为III期疾病的患者中,需要采用多学科方法。只要有条件,患者应优先按照研究方案进行治疗。包括胸壁切除术在内的根治性手术可能导致T3N1疾病的5年生存率高达50%。对于切除边缘不明确的病例,推荐辅助化疗,保留放疗。术前临床试验证实N2患者在术前新辅助化疗或放化疗后达到降低分期的效果更好。可能需要全肺切除术的患者应谨慎选择,因为一些中心的围手术期死亡率很高。如果在手术中发现未预见的N2疾病,建议进行辅助治疗。T4肿瘤(浸润大血管、气管、食道、椎体等)患者如果在经验丰富的中心治疗,根治性切除后的5年生存率从15%增加到35%,围手术期死亡率也可以接受。在III期非小细胞肺癌中,手术应在多模式下进行。当切除是根治性的,包括系统性淋巴结清扫,死亡率和发病率低时,应推荐手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Advances in the planning and delivery of radiotherapy: new expectations, new standards of care. The expanding roles of stereotactic body radiation therapy and oligofractionation: toward a new practice of radiotherapy. Stereotactic body radiation therapy: normal tissue and tumor control effects with large dose per fraction. Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy. Stereotactic body radiation therapy for gastrointestinal malignancies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1